ARTICLE
Quviviq vs Dayvigo — same class, one distinction that decides between them
Both are dual orexin receptor antagonists, so the real question isn't which is newer. It's half-life — and that single difference is what should decide which one you and your clinician choose.
If you are comparing Quviviq (daridorexant) and Dayvigo (lemborexant), you have already narrowed things to the newest class of sleep medication — the dual orexin receptor antagonists, or DORAs. Both block the brain's wake signal rather than sedating you, and neither is meaningfully 'older' or 'weaker' than the other.
That makes this comparison different from most. There is no clear winner in the abstract. There is one axis that genuinely separates them — how long the drug stays in your system — and matching that to how your insomnia actually behaves is the whole decision. Here is the honest version.
| Quviviqdaridorexant | Dayvigolemborexant | |
|---|---|---|
| Mechanism | Dual orexin receptor antagonist — blocks both OX1 and OX2 wake signals | Dual orexin receptor antagonist — blocks both OX1 and OX2 wake signals |
| FDA approval | January 2022 | December 2019 |
| Half-life | ~8 hours — short by design, to limit next-day effects | Effective ~17–39 h; terminal ~45–55 h — substantially longer than Quviviq |
| Standard dose | 25 mg or 50 mg, once nightly | 5 mg, may increase to 10 mg maximum, once nightly |
| Onset & timing | Within 30 min of bed, with ≥7 hours before planned wake | At bedtime, with ≥7 hours before planned wake |
| Next-morning grogginess risk | Lower — the short half-life clears by morning | Higher — measurable impairment 8–9 h after the 10 mg dose; label warns against next-morning driving on 10 mg |
| Controlled-substance status | Schedule IV | Schedule IV |
| Manufacturer | Idorsia | Eisai |
Same class, different half-life — the one distinction that matters
Start with what is not different. Quviviq and Dayvigo are both dual orexin receptor antagonists: they block orexin, the signal your brain uses to stay awake and alert, at both of its receptors (OX1 and OX2). Neither sedates you the way the older Z-drugs and benzodiazepines do, both are Schedule IV controlled substances, and both were approved within a few years of each other — Dayvigo in December 2019, Quviviq in January 2022. On mechanism, they are siblings, not rivals.
What separates them is how long they linger. Quviviq's half-life is roughly 8 hours, and that was a deliberate design choice — daridorexant was engineered to clear quickly, specifically to limit next-day residual effects. Dayvigo is a longer story, and it is worth being precise about it: its half-life is commonly quoted as 17 hours at 5 mg and 19 hours at 10 mg, but the underlying pharmacokinetics show a terminal half-life closer to 45 to 55 hours and an effective half-life somewhere between about 17 and 39 hours depending on dose. However you frame it, the honest summary is the same — lemborexant stays active substantially longer than daridorexant.
That single difference cascades into everything that matters when you are choosing. A shorter half-life means less drug on board by morning — less grogginess, less fog, lower next-day risk — but potentially less coverage deep into the night. A longer half-life means the reverse: more of the night covered, at the cost of more drug still present when the alarm goes off. Neither profile is better in the abstract. The right one depends entirely on which end of the night is failing you.
When Quviviq is the better fit
Quviviq's short half-life is its whole case. If you wake up feeling drugged on other sleep medications, if you drive or do anything cognitively demanding first thing, or if next-day fog is the side effect you most want to avoid, the roughly 8-hour clearance is working in your favor. It is the profile built to minimize the morning-after cost.
The flip side is honest too. If your core problem is waking at 3 or 4am and lying there for an hour, a fast-clearing drug may already be fading by the time you need it most. Quviviq can still help sleep maintenance for many people, but its strength is a clean morning rather than maximal late-night coverage. If daytime performance is non-negotiable for you, that is the trade you are choosing — and it is often the right one.
When Dayvigo is the better fit
Dayvigo's longer duration is its whole case, and it points at a specific pattern: sleep-maintenance insomnia — the early-hours awakening, the 4am ceiling, the inability to get back down in the second half of the night. A drug still meaningfully present at 4am can cover exactly that gap, which is why the longer half-life is a feature and not only a liability.
But the liability is real, and worth stating plainly. Driving-simulator studies found measurable next-morning impairment 8 to 9 hours after the 10 mg dose, and Dayvigo's label carries an explicit warning against next-morning driving at that dose. So the longer coverage comes with a genuine daytime cost, concentrated at the higher dose. Dayvigo makes the most sense when early-hours waking is the dominant problem and your mornings can absorb some residual drug — a judgment to make with a prescriber, not alone.
The honest part — even the newest pill is management, not a cure
Here is what a Quviviq-versus-Dayvigo comparison owes you. Both are genuine advances on one axis — dependence risk — and both are reasonable choices for the right person. But their evidence for actually improving sleep is modest, and whichever you pick, it works only while you keep taking it. Switch from one to the other and you have changed the half-life, not the underlying problem.
That matters most if your nights are the 'tired but wired' kind — an exhausted body and a nervous system that will not switch off. That hyperarousal is what keeps you awake, and turning down one wake signal nightly does not retrain it; tired but wired explains the mechanism. The treatment that does retrain the sleep system — and the one recommended first-line for chronic insomnia, ideally used alongside any medication rather than instead of it — is not a pill at all. It is CBT-I, and the 6-week program is that treatment delivered as a structured, week-by-week path. For the wider set of options beyond these two drugs, the full Quviviq alternatives guide maps them out.
The full Quviviq alternatives guide — the wider map, including the third orexin antagonist and the out-of-class prescription options.
The strongest OTC sleep aids, ranked honestly — the pillar guide to the non-prescription landscape, if a milder approach is what you are weighing.
Tired but wired — the hyperarousal pattern that no nightly pill, at any half-life, resolves.
The 6-week program — CBT-I as a structured path, the treatment recommended first-line for chronic insomnia.
Frequently asked questions
Is Quviviq stronger than Dayvigo?
Not in a meaningful sense — 'stronger' is the wrong frame for two drugs in the same class. Both are dual orexin receptor antagonists that work the same way, and neither is simply more potent than the other. The real difference is half-life: Dayvigo stays active substantially longer, which can mean better coverage of early-hours waking but more next-day residual effect, while Quviviq's roughly 8-hour half-life clears faster for a clearer morning. Which is 'better' depends on your pattern, not on raw strength.
Can you switch from Dayvigo to Quviviq?
It is a common and reasonable switch, and the usual reason is next-day grogginess — moving from the longer-acting Dayvigo to the shorter-acting Quviviq to wake clearer. But it is a prescription change a clinician should manage, including timing and dose, and it is worth being clear about what you are changing: you are swapping half-life profiles, not fixing the underlying insomnia. If the switch is driven by side effects, that is sensible; if it is driven by the drug not working at all, the more useful question is whether a pill is the right tool in the first place.
Which has fewer side effects, Quviviq or Dayvigo?
On next-day effects specifically, Quviviq tends to have the edge, because its shorter half-life means less drug remains in your system in the morning — less grogginess and lower next-day impairment risk. Dayvigo's 10 mg dose in particular carries a label warning against next-morning driving. Otherwise the two share the same class side-effect profile: daytime drowsiness and rare complex sleep behaviors. Individual response varies, so which has fewer for you is something to assess with your prescriber.
Which is better for waking up at 3 or 4am?
For early-hours waking — sleep-maintenance insomnia — the longer-acting drug has a logical advantage, and that is Dayvigo: a medication still meaningfully present at 4am can cover a gap a fast-clearing one may not. The catch is that the same duration is what drives Dayvigo's next-morning risk at the 10 mg dose. Quviviq can still help maintenance for many people, but its strength is a clean morning rather than maximal late-night coverage. This is exactly the trade-off to weigh with a clinician against your specific pattern.
Are Quviviq and Dayvigo the same type of drug?
Yes. Both are dual orexin receptor antagonists (DORAs) — they block orexin, the brain's wake signal, at both of its receptors, rather than broadly sedating you the way benzodiazepines and Z-drugs do. Belsomra (suvorexant) is the third drug in the same class. Because Quviviq and Dayvigo share this mechanism, choosing between them is not about class or novelty; it comes down to half-life and how it matches your sleep pattern.
Sources
- U.S. Food and Drug Administration (FDA) — Prescribing Information for QUVIVIQ (daridorexant), Idorsia Pharmaceuticals: dual orexin receptor antagonism, Schedule IV status, ~8-hour half-life, 25 mg / 50 mg dosing, and class warnings (next-day somnolence, complex sleep behaviors).
- U.S. Food and Drug Administration (FDA) — Prescribing Information for DAYVIGO (lemborexant), Eisai Inc.: dual orexin receptor antagonism, Schedule IV status, half-life and pharmacokinetics, 5 mg / 10 mg dosing, and the warning against next-morning driving at the 10 mg dose.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349.
- Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125–139.
- Rosenberg R, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial (SUNRISE 1). JAMA Netw Open. 2019;2(12):e1918254.